{
    "nct_id": "NCT04216576",
    "official_title": "Oral Self-Management of Palbociclib (IbranceÂ®) Using Mobile Technology",
    "inclusion_criteria": "* Patients with a breast cancer diagnosis who are initiating therapy on palbociclib (Ibrance)\n* >/= 18 years of age\n* Able to speak, read and write English\n* Willingness and ability to send and receive text messages with intervention app\n* Own a mobile telephone \"smartphone\" with text messaging capabilities. Only iPhone or Android operating systems support OhMD Application\n* Criteria applicable for both Control and Intervention groups\n* Flip-phones do not support OhMD Application and thus ineligible to participate\n* Initiation palbociclib (Ibrance) for the first time, either as monotherapy or in conjunction with other medication such as Lstrozole (Femara) or Fulvestrant (Faslodex)\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of taking palbociclib (Ibrance)\n* Patients whose caregivers coordinate their health care",
    "miscellaneous_criteria": ""
}